The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.

Also called NCT06117137

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 150 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06117137
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06117137. Randomized; no masking; primary purpose treatment. Start 2023-11-15 (actual); primary completion 2025-01-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus
Condition
Fatty Liver, Nonalcoholic
Intervention (Drug)
SGLT2 inhibitor
Lead sponsor
Sohag University (class: other)

Record details

Record id
cardio:ct-nct06117137
Content hash
b9a11351545785c1442731f7be7978cb3b9f0ad62b9a4fc76e721cf4a1fb5361